IHE - iShares US Pharmaceuticals ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
148.18
-5.20 (-3.39%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close153.38
Open151.61
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range147.73 - 152.43
52 Week Range139.28 - 170.26
Volume16,938
Avg. Volume19,190
Net Assets417.63M
NAV157.60
PE Ratio (TTM)N/A
Yield1.13%
YTD Return3.01%
Beta (3Y Monthly)1.03
Expense Ratio (net)0.43%
Inception Date2006-05-01
Trade prices are not sourced from all markets
  • ETF Trendsyesterday

    Healthcare ETFs Looked Pale on Reports J&J Knew About Asbestos in Baby Powder

    Healthcare sector-related ETFs appeared sickly Friday as Johnson & Johnson (JNJ) dragged down the segment in response to reports that the company knew for decades that its baby powder contained asbestos. Healthcare stocks retreated after Reuters reported that the pharma giant knew for decades that the cancer-causing asbestos were found in its Baby Powder. In an examination of company memos, internal reports and other confidential documents, Reuters found that J&J known about the presence of trace amounts of asbestos in its products from as early as 1971.

  • Merck’s Keytruda Had 80% Growth in the Third Quarter
    Market Realistlast month

    Merck’s Keytruda Had 80% Growth in the Third Quarter

    Merck & Co.’s (MRK) Keytruda generated revenues of $1.9 billion in the third quarter, reflecting an ~80% YoY growth and a 13% sequential growth. In the US and international markets, Keytruda generated revenues of $1.1 billion and $780 million, respectively, in the third quarter, compared to $604 million and $442 million, respectively, in the third quarter of 2017, reflecting an ~84% YoY growth and a ~76% YoY growth, respectively.

  • A Performance Review of JNJ’s Pulmonary Hypertension Business
    Market Realist2 months ago

    A Performance Review of JNJ’s Pulmonary Hypertension Business

    Johnson & Johnson’s (JNJ) pulmonary hypertension business generated revenue of $656.0 million in the third quarter compared to $632.0 million in the third quarter of 2017, reflecting ~3.8% YoY (year-over-year) growth.

  • 2 months ago

    ETF Plays for a Divided Midterm Elections

    With a contentious midterms election season coming up, many anticipate a split government that could potentially impact the way ETF investors ride the markets ahead. Some expectations point to Democrats winning back the House of Representatives and the Republicans maintaining a narrow hold on the Senate - Republicans currently dominate both chambers. "If the consensus expectation of a divided government turns out to be correct, the most likely political consequences would be an increase in investigations and uncertainty surrounding fiscal deadlines," David Kostin, Goldman's chief U.S. equity strategist, said in a note.

  • Pfizer: Analysts’ Recommendations on October 22
    Market Realist2 months ago

    Pfizer: Analysts’ Recommendations on October 22

    Analysts expect Pfizer’s (PFE) top line to increase ~2.9% to ~$13.5 billion during the third quarter. The company’s EPS is expected to increase to $0.75 in the third quarter—compared to $0.67 in the third quarter of 2017.

  • Pfizer’s Dividends and Earnings Quality
    Market Realist2 months ago

    Pfizer’s Dividends and Earnings Quality

    In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.

  • Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
    Zacks2 months ago

    Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

    Sector ETF report for PPH

  • ETF Trends3 months ago

    Pharmaceutical ETFs Could Maintain Their Momentum

    Pharmaceutical stocks and sector-related exchange traded funds have enjoyed a great summer and the rally may continue to have legs. Meanwhile, the broader iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) rose 10.6%. There were no clear catalysts to explain the rally as we did not witness any memorable earnings beats, new clinical trials or large-scale deals, the Wall Street Journal reports.

  • Investopedia4 months ago

    3 ETFs for Johnson & Johnson's Healthy Breakout

    Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.

  • Comparing Pharmaceuticals ETFs’ June Performance
    Market Realist5 months ago

    Comparing Pharmaceuticals ETFs’ June Performance

    Pharmaceutical ETFs, securities publicly traded on stock markets, are designed for investors who do not have the capacity to hold many stocks but are interested in diversifying their pharmaceutical investments. The chart below compares ETFs’ normalized prices in June.

  • ETF Trends5 months ago

    July Could Be a Volatile Month for Pharma ETFs

    Changing political winds and the seasonal period for drugmakers to hike their prices could trigger short-term volatility in pharmaceutical sector-related ETFs. The markets could put a spotlight on pharmaceutical stocks and the rising cost of drug prices as Mid-term elections are quickly coming up in November and July is a popular month for drug companies to increase list prices on medicines, writes Charley Grant for the Wall Street Journal. Just last week, Health and Human Services Secretary Alex Azar said in congressional testimony that companies should “practice restraint” with price increases.

  • Play the Best Sector of Summer With These ETFs & Stocks
    Zacks6 months ago

    Play the Best Sector of Summer With These ETFs & Stocks

    Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.

  • Pharmaceutical ETFs and Their Performances in May
    Market Realist6 months ago

    Pharmaceutical ETFs and Their Performances in May

    Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.

  • Trump lets drug companies off the hook
    Yahoo Finance7 months ago

    Trump lets drug companies off the hook

    After several delays, President Trump unveiled a plan to lower drug prices. Don't bank on it just yet.

  • Merck’s Segment-Wise Performance in 1Q18
    Market Realist7 months ago

    Merck’s Segment-Wise Performance in 1Q18

    Merck’s (MRK) products are classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck’s revenue grew 6% to ~$10.0 billion in 1Q18, driven by 3% operating revenue growth and a 3% boost by foreign exchange.

  • Allergan’s US Specialized Therapeutics Segment in 1Q18
    Market Realist7 months ago

    Allergan’s US Specialized Therapeutics Segment in 1Q18

    As we discussed previously in this series, Allergan’s (AGN) US Specialized Therapeutics segment includes the revenues from the US sales of specialized products related to eye care, medical aesthetics, dermatology, neuroscience, and urology. The chart below compares the revenues for the US Specialized Therapeutics segment since 1Q17.

  • Pfizer Reports 1Q18 Earnings and Revenue Growth
    Market Realist7 months ago

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business. The company reported 1% growth in its revenues to $12.9 billion for 1Q18, compared to ~$12.8 billion in 1Q17.

  • Why Analysts Expect Pfizer to See Revenue Growth in 1Q18
    Market Realist8 months ago

    Why Analysts Expect Pfizer to See Revenue Growth in 1Q18

    As discussed in the previous part of this series, Wall Street analysts estimate Pfizer’s (PFE) revenues will increase ~2.7% to $13.1 billion during 1Q18 as compared to revenues of $12.8 billion during 1Q17. The growth in revenues is expected to be driven by innovative health products. Pfizer’s products are classified into two business segments: the Innovative Health segment and the Essential Health segment.

  • Allergan’s 1Q18 Estimates: Expect Growth in Revenues
    Market Realist8 months ago

    Allergan’s 1Q18 Estimates: Expect Growth in Revenues

    As we discussed earlier, analysts expect Allergan’s (AGN) revenues to see 0.6% growth to $3.6 billion during 1Q18. Allergan classifies its business operations into three business segments: US Specialized Therapeutics US General Medicines International 

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realist8 months ago

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist8 months ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
    Zacks8 months ago

    Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

    Sector ETF report for PPH

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist8 months ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist8 months ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.